Thermo Fisher Scientific (TMO) → Stock, financial statements

Thermo Fisher Scientific: stocks, financial statements

Dividends News

Thermo Fisher Scientific, Inc. engages in the provision of analytical instruments, equipment, reagents and consumables, software and services for research, analysis, discovery, and diagnostics. It operates through the following segments: Life Sciences Solutions; Analytical Instruments; Specialty Diagnostics; and Laboratory Products and Services. The Life Sciences Solutions segment comprises of portfolio of reagents, instruments, and consumables used in biological and medical research, discovery and production of new drugs, and vaccines as well as diagnosis of disease. The Analytical Instruments segment offers instruments, consumables, software, and services that are used for a range of applications in the laboratory, on the production line, and in the field. The Specialty Diagnostics segment gives diagnostic test kits, reagents, culture media, instruments, and associated products used to increase the speed and accuracy of diagnoses. The Laboratory Products and Services segment involves in providing everything needed for the laboratory, including a combination of self-manufactured and sourced products for customers in research, academic, government, industrial, and healthcare settings. The company was founded on October 11, 1960 and is headquartered in Waltham, MA.

  • TMO Ticker
  • 🇺🇸 NYSE Exchange
  • 70,000 Employees
5 rated

Financial statements — Thermo Fisher Scientific

The information is not 100% up-to-date. There may be errors or missing information. Some information is often missing, and, although there are almost no errors, I can't rule them out. Right now, I'm looking for a supplier of high-quality information, but so far what I'm finding is expensive (about $2000 a year). You can help my project here.
20 ← 16 2020 2019 2018 2017 2016
Total Revenue
32B 26B 24B 21B 18B
Cost Of Revenue
16B 14B 14B 11B 9.9B
Gross Profit
16B 11B 11B 9.4B 8.4B
Research and Development
1.2B 1B 970M 890M 750M
Selling General and Admin
6.9B 6.1B 6.1B 5.5B 5B
Operating Expense
24B 21B 21B 18B 16B
Operating Income
7.9B 4.2B 3.8B 3.1B 2.6B
Other Income Expense Net
0 0 0 0 0
7.9B 4.2B 3.8B 3.1B 2.6B
Interest Income
490M 450M 530M 510M 420M
Pretax Income
7.2B 4.1B 3.3B 2.4B 2B
Income Tax
850M 370M 320M 200M -1.4M
Minority Interest
0 0 0 0 0
Net Income
6.4B 3.7B 2.9B 2.2B 2B
Net Income Basic
6.4B 3.7B 2.9B 2.2B 2B
20 ← 16 2020 2019 2018 2017 2016
Current cash
10B 2.4B 2.1B 1.3B 790M
Short term investments
1.9B 1.8B 1.4B 1.2B 970M
5.7B 4.3B 4.1B 3.9B 3B
4B 3.4B 3B 3B 2.2B
Other current assets
1.9B 1.8B 1.4B 1.2B 970M
Current assets
22B 12B 11B 9.4B 7B
Long term investments
47B 46B 46B 47B 39B
Property plant equipment
5.9B 4.7B 4.2B 4B 2.6B
26B 26B 25B 25B 21B
Intangible assets
13B 14B 15B 17B 14B
Other assets
2.5B 2B 1.1B 1.2B 970M
Total assets
69B 58B 56B 57B 46B
Accounts payable
2.2B 1.9B 1.6B 1.4B 930M
Current long term debt
2.6B 680M 1.3B 2.1B 1.3B
Other current liabilities
5.5B 3.6B 3.3B 3.5B 2.7B
Total current liabilities
10B 6.2B 6.1B 7B 4.9B
Long term debt
19B 17B 18B 19B 15B
Other liabilities
3.3B 3.2B 2.5B 2.6B 1.6B
Minority Interest
0 0 0 0 0
Total Liabilities
35B 29B 29B 31B 24B
Common stock
400M 400M 400M 400M 390M
Retained earning
28B 22B 19B 16B 14B
Treasury stock
-6.8B -5.2B -3.7B -3.1B -2.3B
Capital surplus
Shareholder equity
35B 30B 28B 25B 22B
Net tangible assets
-4.2B -10B -13B -17B -14B
20 ← 16 2020 2019 2018 2017 2016
Net Income
6.4B 3.7B 2.9B 2.2B 2B
2.3B 2.3B 2.3B 2B 1.8B
Changes in receivables
1.4B 210M 260M 830M 500M
Changes in inventories
660M 370M 34M 760M 220M
Cash change
7.9B 300M 770M 550M 330M
Cash flow
8.3B 5B 4.5B 4B 3.2B
Capital expenditures
-1.5B -930M -760M -510M -440M
Investing activity other
Total investing cash flows
-1.5B -1.5B -1.3B -7.7B -5.5B
Dividends paid
Net borrowings
9.5B 14B 16B 18B 15B
Other financing cash flows
Cash flow financing
960M -3.1B -2.2B 3.9B 2.9B
Exchange rate effect